lower schreef op 21 januari 2016 10:47:
Ik, 5 jaar in Pharming, wil ook snel heel veel hyperbiotech centjes verdienen ;-)
Ik zie Pharming als een ontwikkelbedrijf dat hopelijk interessant wordt voor een grote Pharma.
seekingalpha.com/article/3582366-why-...Summary
Many investors consider biotech stocks to be risky bets but few are aware of the global context which brought the recent revaluations of many companies in the sector.
After decades of research, enduring small-cap biotechs are reaching late-stage developments and coming close to market approval of their drugs.
On the other side, big pharma companies which massively divested R&D activities in the last decade are now structurally on the lookout for potential acquisition candidates.
In this context, savvy investors might want to pick biotech stocks which display the right combination of technological maturity and market perspective.
Hence, with a good knowledge of the sector and the right investment horizon, there is still considerable profit to be made in the coming years.